Dexanabinol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dexanabinol" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

5web.archive.org

1^st place

5doi.org

2^nd place

3etherapeutics.co.uk

low place

2clinicaltrials.gov

5,225^th place

4,062^nd place

1harvard.edu

18^th place

17^th place

1semanticscholar.org

11^th place

8^th place

1laboratoryequipment.com

low place

1unodc.org

2,494^th place

2,269^th place

1usdoj.gov

2,755^th place

1,753^rd place

1erowid.org

3,887^th place

3,197^th place

1legiscan.com

low place

1state.fl.us

2,917^th place

1,621^st place

1healthvermont.gov

low place

clinicaltrials.gov

"A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours". ClinicalTrials.gov. NIH. January 26, 2015.
"A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-09-18.

doi.org

Pop E (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design. 6 (13): 1347–60. doi:10.2174/1381612003399446. PMID 10903397.
Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584–7. Bibcode:1989PNAS...86.9584F. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.
Biegon A, Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research. 17 (4): 275–80. doi:10.1080/01616412.1995.11740326. PMID 7477742.
Vink R, Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics. 6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMC 5084254. PMID 19110197.
Maas AI, Murray G, Henney H, Kassem N, Legrand V, Mangelus M, et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". The Lancet. Neurology. 5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021. S2CID 28268833.

erowid.org

Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary

etherapeutics.co.uk

"e-therapeutics Clinical Development Pipeline". Archived from the original on 2013-01-26. Retrieved 2012-10-23.
"e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies" (PDF). 18 December 2014. Archived from the original (PDF) on 5 February 2015.
"Clinical Development Pipeline". Archived from the original on February 5, 2015. Retrieved Feb 5, 2015.

harvard.edu

ui.adsabs.harvard.edu

Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584–7. Bibcode:1989PNAS...86.9584F. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.

healthvermont.gov

Vermont DOH - Regulated Drug Rule 2016 .PDF

laboratoryequipment.com

University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

legiscan.com

"Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd". March 2014. Retrieved 2 February 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pop E (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design. 6 (13): 1347–60. doi:10.2174/1381612003399446. PMID 10903397.
Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584–7. Bibcode:1989PNAS...86.9584F. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.
Biegon A, Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research. 17 (4): 275–80. doi:10.1080/01616412.1995.11740326. PMID 7477742.
Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs. 6 (10): 976–9. PMID 14534855.
Vink R, Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics. 6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMC 5084254. PMID 19110197.
Maas AI, Murray G, Henney H, Kassem N, Legrand V, Mangelus M, et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". The Lancet. Neurology. 5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021. S2CID 28268833.

ncbi.nlm.nih.gov

Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584–7. Bibcode:1989PNAS...86.9584F. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.
Vink R, Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics. 6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMC 5084254. PMID 19110197.

semanticscholar.org

api.semanticscholar.org

Maas AI, Murray G, Henney H, Kassem N, Legrand V, Mangelus M, et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". The Lancet. Neurology. 5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021. S2CID 28268833.

state.fl.us

leg.state.fl.us

Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL

unodc.org

"UN International Drug Control Conventions". Archived from the original on 2014-03-17. Retrieved 2016-08-07.

usdoj.gov

deadiversion.usdoj.gov

"§1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.

web.archive.org

"e-therapeutics Clinical Development Pipeline". Archived from the original on 2013-01-26. Retrieved 2012-10-23.
"e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies" (PDF). 18 December 2014. Archived from the original (PDF) on 5 February 2015.
"Clinical Development Pipeline". Archived from the original on February 5, 2015. Retrieved Feb 5, 2015.
"UN International Drug Control Conventions". Archived from the original on 2014-03-17. Retrieved 2016-08-07.
"§1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.